spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

HATRIC-based identification of receptors for orphan ligands (small molecules)


HATRIC-LRC (Ligand Receptor Capture) enables now the identification of small molecule targets on the surface of living cells! Even primary cells!

In their latest publication, the Wollscheid group (ETH Zurich, Switzerland) demonstrated how HATRIC-LRC can be used to identify orphan ligand targets from as few as 1 million cells, enabling the LRC technology to be performed on rare primary cells or clinical specimens. What is more, next to de-orphaning proteins, viruses and antibodies, HATRIC-LRC can now be used to identify the unknown targets of small molecules on the cell membrane of living cells in order to elucidate the mode of action of the molecule of interest.

Nadine Sobotzki, Michael A. Schafroth, Alina Rudnicka, Anika Koetemann, Florian Marty, Sandra Goetze, Yohei Yamauchi, Erick M. Carreira & Bernd Wollscheid

Nature Communications, volume 9, Article number: 1519 (2018) doi:10.1038/s41467-018-03936-z,

Published online: 17 April 2018

Abstract

Cellular responses depend on the interactions of extracellular ligands, such as nutrients, growth factors, or drugs, with specific cell-surface receptors. The sensitivity of these interactions to non-physiological conditions, however, makes them challenging to study using in vitro assays. Here we present HATRIC-based ligand receptor capture (HATRIC-LRC), a chemoproteomic technology that successfully identifies target receptors for orphan ligands on living cells ranging from small molecules to intact viruses. HATRIC-LRC combines a click chemistry-based, protein-centric workflow with a water-soluble catalyst to capture ligand-receptor interactions at physiological pH from as few as 1 million cells. We show HATRIC-LRC utility for general antibody target validation within the native nanoscale organization of the surfaceome, as well as receptor identification for a small molecule ligand. HATRIC-LRC further enables the identification of complex extracellular interactomes, such as the host receptor panel for influenza A virus (IAV), the causative agent of the common flu.

 
Print this page
Send to a friend
   
spacer
News and Press Releases

IATA CEIV Pharma certificate of Turkish Cargo renewed

Turkish Cargo, the air cargo brand flying to the most countries around the world, extended the validity period of its IATA CEIV (Center of Excellence for Independent Validators) Pharma certificate to 2022, proving its success in all processes throughout the air transportation of medicinal products.
More info >>


White Papers

PhlexEarchive: The Right Solution for Electronic Archiving of TMF Content

Phlexglobal Ltd

Many sponsor organizations have already recognized the value of moving from paper to electronic Trial Master Files (eTMFs). But few sponsors have taken a more holistic approach to the TMF lifecycle and looked at the entire process from study start-up through archiving of the TMF in electronic format, also known as e-archiving. The recurring value of managing, tracking, maintaining and accessing electronic files should not stop at the point of archiving. All of the challenges of managing an active paper TMF carry through to a paper archive. All of the benefits of an electronic TMF also carry through to the electronic archive. As companies look to move their compliance assets to secure, long-term storage, it is important to consider ongoing compliance requirements, security, accessibility, efficiency and costs of archiving TMF content in a digital format.
More info >>

Industry Events

ESMO Targeted Anticancer Therapies Congress 2020

2-4 March 2020, Paris, France

A unique and international mix of experts, researchers and decision makers both from academia and industry across the globe, will convene in Paris for a three-day Congress aiming at exchanging knowledge, experience and research innovations in cancer. TAT 2020 will focus, among others, on novel strategies in immuno-oncology, personalised medicine and molecular tumour boards, preclinical studies to identify effective combination therapies, use of microbiome, tumour agnostic trials, ADC technology, oncolytics, multispecific biological constructs and targeting cytokines. Participating in TAT 2020 will offer you the possibility to take part in interdisciplinary discussions inspiring new ideas and new collaborations.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement